Breakthrough: Liraglutide Cuts Migraine Frequency by Over 50%
 |
| A person self-injecting liraglutide while sitting with a migraine relief pack, symbolizing the dual purpose of the medicationi |
A well-known diabetes and weight-loss medication, liraglutide, has shown promising results in significantly reducing chronic migraine attacks—offering new hope to sufferers. The GLP‑1 receptor agonist cut monthly migraine days in half by modulating cerebrospinal fluid pressure.
Study Highlights
- Conducted at the Headache Centre, University of Naples Federico II.
- Presented at the 2025 European Academy of Neurology (EAN) Congress in Helsinki, reported by EurekAlert and covered by multiple outlets .
- Involved 26 obese adults with chronic migraine (≥15 headache days/month).
- A daily 1.2 mg injection of liraglutide led to an average reduction of 11 fewer migraine days per month, and a ~35‑point drop on the MIDAS scale—boosting productivity and daily functioning .
- Minimal weight loss seen (BMI from ~34.0 to ~33.65); statistical analysis linked migraine reduction to pressure modulation, not weight loss .
How Liraglutide Works Against Migraines
GLP‑1 receptor agonists alter cerebrospinal fluid production, lowering intracranial pressure and potentially reducing CGRP (calcitonin gene-related peptide), a key player in migraine mechanisms .
Researchers believe this pressure-modulating effect, rather than metabolic changes, underlies migraine relief .
Side Effects & Patient Response
- ≈38% experienced mild gastrointestinal symptoms—nausea, constipation—but none discontinued treatment .
- Most reported noticeable improvements within 2 weeks, sustained over the 12-week study period .
Future Directions
Researchers aim to explore other GLP‑1 agonists like semaglutide or dulaglutide to confirm effects with possibly fewer side effects, and to conduct larger randomized controlled trials in broader populations .
Final Takeaway
Liraglutide represents a novel, non-traditional approach to migraine prevention—targeting intracranial pressure control rather than purely metabolic pathways. While results are promising, more robust clinical trials are needed before widespread clinical use.